


CLAIMS

1. The use of a compound containing a high density, negatively charged domain of vicinally oriented radicals for the preparing of a medicament providing a growth factor modulating activity in mammals including man.
2. The use according to claim 1 wherein the negatively charged domain comprises at least three vicinal phosphorus-containing radicals.
3. The use according to claim 1 wherein the phosphorus-containing radicals have the following formula:



wherein

V^1 to V^4 are $\text{Y}^8_{m6}\text{T}_{o3}\text{U}$

T_{o1} to T_{o3} are $(\text{CH}_2)_n$, CHCH_1 , or $\text{CH}_2\text{CHCHCH}_2$,

$o1$ to $o3$ are 0 or 1

n is 0 to 4;

U is $\text{R}^1\text{Y}^9_{m7}$, $\text{CY}^{10}\text{Y}^{11}\text{R}^2$, $\text{SY}^{12}\text{Y}^{13}\text{Y}^{14}\text{R}^3$, $\text{PY}^{15}\text{Y}^{16}\text{Y}^{17}\text{R}^4\text{R}^5$,
 $\text{Y}^{18}\text{PY}^{19}\text{Y}^{20}\text{Y}^{21}\text{R}^6\text{R}^7$, CH_2NO_2 , NHSO_2R^8 , or $\text{NHCY}^{22}\text{Y}^{23}\text{R}^9$,

$m1$ to $m7$ are 0 or 1;


Y^1 to Y^{23} are NR^{10} , NOR^{11} , O, or S;

and where R^1 to R^{11} are

- i) hydrogen
- ii) a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms
- iii) a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon atoms and 0-5 heteroatoms consisting of nitrogen, oxygen or sulfur

- iv) a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms substituted with a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon and 0-5 heteroatoms consisting of nitrogen, oxygen, or sulfur
 - v) an aromatic or non-aromatic homo- or heterocyclic residue containing 3-22 carbon and 0-5 heteroatoms consisting of nitrogen, oxygen, or sulfur substituted with a straight or branched saturated or unsaturated alkyl residue containing 1-22 carbon atoms.
- in the said groups ii-v the residues and/or the substituents thereof being substituted with 0-6 of the following groups: hydroxy, alkoxy, aryloxy, acyloxy, carboxy, alkoxy carbonyl, alkoxy carbonyloxy, aryloxycarbonyl, aryloxycarbonyloxy, carbamoyl, fluoro, chloro, bromo, azido, cyano, oxo, oxa, amino, imino, alkylamino, arylamino, acylamino, arylazo, nitro, alkylthio or alkylsulfonyl.

4. The use according to claim 3 wherein the phosphorus-containing radicals have the following formula:



wherein V^1 and V^2 are OH, $(\text{CH}_2)_p\text{OH}$, COOH, CONH₂, CONOH, $(\text{CH}_2)_p\text{COOH}$, $(\text{CH}_2)_p\text{CONH}_2$, $(\text{CH}_2)_p\text{CONOH}$, $(\text{CH}_2)_p\text{SO}_3\text{H}$, $(\text{CH}_2)_p\text{SO}_3\text{NH}_2$, $(\text{CH}_2)_p\text{NO}_2$, $(\text{CH}_2)_p\text{PO}_3\text{H}_2$, $\text{O}(\text{CH}_2)_p\text{OH}$, $\text{O}(\text{CH}_2)_p\text{COOH}$, $\text{O}(\text{CH}_2)_p\text{CONH}_2$, $\text{O}(\text{CH}_2)_p\text{CONOH}$, $\text{O}(\text{CH}_2)_p\text{SO}_3\text{H}$, $\text{O}(\text{CH}_2)_p\text{SO}_3\text{NH}_2$, $\text{O}(\text{CH}_2)_p\text{NO}_2$, $\text{O}(\text{CH}_2)_p\text{PO}_3\text{H}_2$ or CF_2COOH
 p is 1 to 4.

5. The use according to claim 3 wherein the phosphorus-containing radicals are phosphate groups.

6. The use according to claim 1 wherein a backbone to the high density negatively charged region of vicinally oriented radicals is a cyclic moiety.

7. The use according to claim 6 wherein the backbone is a saturated or unsaturated aromatic or non-aromatic homo- or heterocyclic moiety where the heteroatom is nitrogen, oxygen, sulfur or selenium.

8. The use according to claim 7 wherein the cyclic moiety comprises 4 to 24 atoms, preferably 5 to 18 atoms.
9. The use according to claim 7 wherein the cyclic moiety is selected from the group of cyclopentane, cyclohexane, cycloheptane, inositol, monosaccharide, disaccharide, trisaccharide, tetrasaccharide, piperidin, tetrahydrothiopyran, 5-oxotetrahydrothiopyran, 5,5-dioxotetrahydrothiopyran, tetrahydroselenopyran, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, 5-oxotetrahydrothiophene, 5,5-dioxotetrahydrothiophene, tetrahydroselenophene, benzene, cumene, mesitylene, naphthalene and phenanthrene.
10. The use according to claim 7 wherein the cyclic moiety is selected from the group of alioinositol, cisinositol, ipiinositol, D/L-chiroinositol, scylloinositol, myoinositol, mycoinositol and neoinositol.
11. The use according to claim 7 wherein the cyclic moiety is selected from the group of D/L-ribose, D/L-arabinose, D/L-xylose, D/L-lyxose, D/L-allose, D/L-altrose, D/L-glucose, D/L-mannose, D/L-gulose, D/L-idose, D/L-galactose, D/L-talose, D/L-ribulose, D/L-xylulose, D/L-psicose, D/L-sorbose, D/L-tagatose, and D/L-fructose.
12. The use according to claim 7 wherein one of the phosphorus-containing radicals is axial and two of the phosphorus-containing radicals are equatorial.
13. The use according to claim 12 wherein the compound is selected from the group of myo-inositol-1,2,6-trisphosphate, mannose-2,3,4-trisphosphate, rhamnose-2,3,4-trisphosphate, galactose, 2,3,4-trisphosphate, methyl-6-O-butyl- α -D-manno pyranoside-2,3,4-trisphosphate, 1,5-anhydro-D-arabinitol-2,3,4-trisphosphate, fructose-2,3,4-trisphosphate, 1,2-O-ethylene- β -D-fructopyranoside-2,3,4-trisphosphate, cyclohexane-1,2,3-triol trisphosphate, 1,5-dideoxy-1,5-iminoarabinitol-2,3,4-trisphosphate, altrose-2,3,4-trisphosphate, methyl-6-O-butyl- α -D-altropyranoside 2,3,4-trisphosphate or derivatives thereof.
14. The use according to claim 1 wherein the compound is administered by parenteral or non-parenteral administration.
15. The use according to claim 1 wherein the effective amount is from about 0.1 to about 100 mg per kg bodyweight of the animal or man.

16. The use according to claim 1 wherein the agent is in unit dosage forms comprising tablets, granules, capsules, solutions or suspensions.
17. A process of modulating growth factor activity by using a compound according to claims 1-16.